HCA Healthcare dropped from Russell growth indices, shares trade near TD Cowen’s lowered target
29.06.2026 - 10:46:50 | ad-hoc-news.de
HCA Healthcare (US40412C1018) enters the new week with a notable index shift. The hospital operator’s shares trade on the NYSE, following their late June removal from several Russell growth benchmarks, according to recent index rebalancing disclosures.
What the Russell exit means
HCA Healthcare, Inc. was removed in late June 2026 from the Russell 1000 Growth, Russell Top 200 Growth and related Russell 3000E growth benchmarks as part of the annual reconstitution, according to index coverage summarised by MarketScreener and Simply Wall St. The changes follow FTSE Russell’s yearly methodology-driven reshuffle, which adjusts membership based on updated style classifications and market capitalisation. The exit from these growth indices may modestly affect passive ownership, as index-tracking funds realign holdings in line with the new compositions, but it does not alter HCA’s underlying operations or financial guidance.
The index removal coincides with ongoing leadership transition at the company. HCA earlier announced that Executive Vice President and Chief Clinical Officer Dr. Michael Cuffe will step down from his role effective August 31, 2026, moving into an advisory position until February 2027, as reported in corporate news summaries. Governance observers often track such C-suite changes closely, particularly in healthcare systems where clinical leadership can influence quality metrics, patient outcomes and regulatory relationships.
Analysts adjust price targets
Alongside the index changes, several research houses have recently revisited their views on HCA Healthcare. TD Cowen cut its price target on HCA to 431 dollars from 500 dollars on June 22, 2026, while maintaining a Buy rating, according to a research note cited by Yahoo Finance. The firm said it reduced 2026 and 2027 growth assumptions after its May hospital survey showed flat year-over-year revenue and weaker surgical volumes, partly offset by growth in medical cases. TD Cowen’s stance signals a more cautious growth trajectory but still reflects confidence in HCA’s earnings and cash flow profile.
Other analysts have also fine-tuned their models. Bernstein adjusted its price target on HCA Healthcare to 413 dollars from 503 dollars and kept a Market Perform rating in an early June update, according to MarketScreener’s compilation of broker actions. In May, JPMorgan lowered its target to 490 dollars from 535 dollars while reiterating a Neutral rating, and Argus revised its target to 500 dollars from 560 dollars while keeping a Buy recommendation. These moves collectively indicate that while the stock remains widely covered with predominantly positive or neutral ratings, the sell side has moderated expectations compared with earlier, more optimistic forecasts.
Where the shares trade now
HCA Healthcare shares continue to change hands close to the mid-390 dollar range. Recent quote data from MarketScreener show the stock at around 391.68 dollars, with the level reflecting a small daily gain of about 1.22 percent at the time of the latest update and a roughly 4.40 percent move over a recent period, while still about 16 percent below a prior high watermark. A separate price snapshot on MarketBeat records HCA at 391.96 dollars at the June 26, 2026 close, with modestly higher prints in extended trading, underscoring that the shares currently trade below the more conservative analyst targets but within sight of TD Cowen’s 431 dollar objective. Volatility assessments from TradingKey, which list HCA at approximately 386.94 dollars in a recent check, also frame the stock as a large-cap healthcare name with moderate price swings compared with more volatile sectors.
Index membership changes can influence trading patterns, particularly around the effective date of the Russell reconstitution when index funds rebalance positions. However, the cited price data suggest HCA shares have remained relatively orderly, without outsized short-term dislocations, as investors digest both the benchmark exits and the analyst target resets. For portfolio managers, HCA now sits outside several growth-style indices but still remains in broader market composites, and its large market capitalisation and NYSE listing keep it firmly on the radar of institutional and retail investors alike.
Further news and data on the HCA Healthcare shares
All current corporate disclosures, price data and analyst commentary on HCA Healthcare can be found in the dedicated topic section and on the company’s Investor Relations page.
The business behind the stock
HCA Healthcare operates one of the largest for-profit hospital networks in the United States, with operations concentrated in high-growth urban and suburban markets. The group runs general acute care hospitals, freestanding surgery centers and emergency rooms, and provides a broad spectrum of clinical services ranging from inpatient surgical procedures and cardiology to obstetrics and intensive care. In addition, HCA manages outpatient clinics and diagnostic facilities, extending its reach into ambulatory care and leveraging scale to negotiate with payers and suppliers.
Beyond core hospital operations, HCA has been expanding its presence in healthcare education. On May 27, 2026, the company agreed to acquire The College of Health Care Professions, a provider of allied health training programs, according to news wire coverage summarised by MarketScreener. The deal is intended to strengthen HCA’s pipeline of nurses and allied health workers, supporting staffing needs in its hospitals and care facilities. Education and workforce development have become strategic levers for large health systems seeking to manage labor costs and address shortages in critical clinical roles.
Where the stock trades today
HCA Healthcare shares (US40412C1018) trade on the NYSE around the 391.68 dollar mark in recent data, with a market capitalisation in the tens of billions of dollars and classification in the U.S. healthcare providers and services sector. The stock is included in major U.S. equity benchmarks but has recently been reclassified out of several Russell growth indices, as noted above, while remaining a widely followed large-cap healthcare name.
For investors, HCA Healthcare’s equity reflects a combination of cyclical hospital utilisation trends, payer mix dynamics and the company’s own capital allocation policies, including investment in facilities, education assets and selective acquisitions. Analyst target cuts from TD Cowen, Bernstein, JPMorgan and Argus frame a more measured near-term growth outlook, yet the shares still trade close enough to these revised targets to keep valuation and earnings expectations in active focus among market participants.
Key data on the HCA Healthcare shares
- Company: HCA Healthcare, Inc.
- ISIN: US40412C1018
- WKN: A1CY4D
- Ticker: HCA
- Trading venue: NYSE
- Price (as of 2026-06-26, 15:59): 391.96 USD
- Market cap: approximate large-cap range in tens of billions USD (as of 2026-06-26)
- Sector / industry: Healthcare providers and services
- Index membership: Broad U.S. equity indices; recently removed from Russell 1000 Growth and related Russell growth benchmarks
- Next earnings date: not officially scheduled
Disclaimer: This article provides general, fact-based information on HCA Healthcare, Inc. shares and does not constitute investment advice, a buy or sell recommendation, or a solicitation to trade any financial instrument. Investors should conduct their own research or consult a licensed financial advisor before making investment decisions.
